

Presented by Psychedelics.media
Psychedelic Roundtable Symposium
An international gathering of clinicians, researchers, pharmaceutical leaders and investors examining the science, clinical pathways and commercial future of psychedelic medicine.

About PRS27
Psychedelic medicine is entering a critical phase of development. PRS27 brings together the people advancing its clinical evidence, pharmaceutical innovation, healthcare delivery and commercial infrastructure.
Australia has emerged as an important international market after regulatory changes permitting authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression under specific conditions.

Saturday 20 March 2027
11:55 AM–12:30 PM
Title Sponsor Keynote
Keynote title to be announced.
Former Managing Director, iNova Pharmaceuticals Philippines; General Manager, Janssen Pharmaceutica Philippines; Managing Director, Johnson & Johnson Vietnam. BSc (Flinders), MBA (Deakin).

Title Sponsor: Entropy Neurodynamics
Australian biotechnology company developing psychedelic medicines, including TRP-8803, an intravenous psilocin programme.
Patient acquisition, clinical adoption and building a sustainable market.
From clinical evidence to real-world treatment.
Science, clinical trials and the pharmaceutical pipeline.
The framework for wider patient access.
Financing the future of psychedelic medicine.
Transforming psychedelic medicine through innovation.
Preparing the next generation of professionals.
Friday roundtable
Saturday roundtable
Seven conversations shaping the future of psychedelic medicine.
1
PANEL DISCUSSION 1
Lessons from a decade of clinical adoption, regulation, patient access and commercial development in Australia.
2
PANEL DISCUSSION 2
Building sustainable, scaled and patient-centred models for psychedelic-assisted therapy in Australia and beyond.
3
PANEL DISCUSSION 3
Emerging compounds, new formulations and the next wave of clinical innovation.
4
PANEL DISCUSSION 4
The frameworks needed to support safe, scaled and sustainable access to psychedelic medicine.
5
PANEL DISCUSSION 5
Building a viable and scalable psychedelic medicine industry in the Asia-Pacific region.
6
PANEL DISCUSSION 6
How new technologies, data and AI are improving safety, access and outcomes in psychedelic medicine.
7
PANEL DISCUSSION 7
Building the people, training and professional pathways for a sustainable psychedelic medicine sector.
programme speakers

Executive Producer / Editor, Psychedelics.media

Chair, Australian Multidisciplinary Association for Psychedelic Practitioners (AMAPP)
A registered psychologist, social worker and psychedelic-assisted therapy practitioner. As Chair of AMAPP, she advocates for evidence-informed psychedelic practice and professional standards.

Consultant Psychiatrist, Forest Medicine
Consultant psychiatrist and TGA Authorised Prescriber in psychedelic-assisted therapies, with a particular interest in emerging approaches to psychedelic-assisted therapy.

Director of Medicine, Ipswich Hospital; Chief Medical Officer, MINDR
Director of Medicine at Ipswich Hospital and Senior Lecturer at The University of Queensland, with expertise in clinical pharmacology and toxicology. As Chief Medical Officer of MINDR, he provides medical leadership for its approach to innovative mental health treatments.

Physician and Senior Lecturer, The University of Queensland; CEO, MINDR
A specialist in General Medicine, focused on advancing new approaches to mental healthcare. As CEO of MINDR, he works on translating emerging evidence into practical clinical applications.

Head of the School of Medicine and Psychology, Australian National University
An academic psychiatrist who has conducted an extensive series of clinical trials developing new treatments for mental health conditions. He established the first national psychedelic therapies outcomes registry.

Director of Psychiatry Research, Paratus Clinical; Associate Professor, Australian National University
A neuroscientist whose work includes the development and clinical investigation of psychedelic therapies, including large multi-site clinical trials.

Associate Professor; Consultant Addiction Psychiatrist, Monash University Malaysia
Works in addiction psychiatry, substance use and dual diagnosis. Honorary Secretary of the Addiction Medicine Association of Malaysia, with more than 110 peer-reviewed papers.

Co-Founder and CEO, Safar
Co-Founder and CEO of Safar, an agentic care platform for therapists and wellness practitioners. A technology executive with more than 20 years in sales and leadership.

Men's Mental Health Advocate. A music industry veteran and mastering engineer who speaks openly about addiction, trauma and recovery.

Natural MedTech. Works at the intersection of pharmaceutical innovation, commercialisation and patient access.

Programs and Innovation Lead, Karuna Mental Health; Director, Anam Cara Centre
A multidisciplinary researcher, educator and contemplative therapist working at the intersection of psychedelic-assisted therapy, immersive technology and mental healthcare.

Director of Network and Outreach, Students for Sensible Drug Policy; Community Engagement Manager, Fireside Project
An educator, consultant and harm reduction advocate with more than 15 years of experience in the psychedelic field. Her work spans practitioner training and community engagement.

Executive Director, Ancient Modern Institute; Neuroscience Student and Researcher, Johns Hopkins University
Additional international speakers, industry executives and investment representatives to be announced. Final participation, titles and sessions subject to confirmation.
For eligible students and emerging professionals.
19 & 20 March
Principal benefit: VIP Dinner admission
Opening Networking Ticket · 19 March · AU$95.
Access to the Official Welcome Networking Reception (5:00–7:00 PM) only.
Venue and networking
20 Bourke Street, Melbourne, Victoria
19–20 March 2027
In the CBD near Parliament House and the theatre precinct. Melbourne is recognised for its medical research institutions, universities, healthcare expertise and biotechnology sector.
19 March, 5:00–7:00 PM
20 March, 4:30–6:00 PM
20 March, 7:00–9:00 PM
For VIP delegates, selected speakers, investors, senior clinicians, researchers, healthcare executives and invited industry guests. Subject to availability.
Programme
Time | Session |
|---|---|
1:00–3:00 PM | Registration and delegate arrivals |
3:00–3:45 PM | Opening Industry PanelWhat Can Psychedelic Medicine Learn from the Medicinal Cannabis Industry? Patient acquisition, clinical adoption and building a sustainable market. |
3:45–4:00 PM | Break |
4:00–5:00 PM | Executive RoundtableFrom Emerging Medicine to Established Healthcare Industry |
5:00–7:00 PM | Official Welcome Networking Reception |
Programme · Morning
Time | Session |
|---|---|
8:45–9:30 AM | Registration, tea, coffee and networking |
9:30–9:40 AM | Official Welcome |
9:40–10:20 AM | Panel 1 · Clinical Models and Patient AccessProposed: Dr Julian Dodemaide, Dr Mitchell McKean, Dr Chris Corney |
10:20–11:00 AM | Panel 2 · Research and Next-Generation TherapiesProposed: Professor Paul Fitzgerald, Dr Bernadette Fitzgibbon, Dr Anne Yee |
11:00–11:15 AM | Morning tea |
11:15–11:55 AM | Panel 3 · Regulation, Policy and ReimbursementProposed: Dr Alana (Lani) Roy, Chair, AMAPP Additional panellists to be announced. |
Programme · Afternoon
Programme and proposed speaker allocations are subject to confirmation.
Time | Session |
|---|---|
11:55 AM–12:30 PM | Title Sponsor KeynoteJason Carroll, CEO, Entropy Neurodynamics |
12:30–1:15 PM | Networking lunch |
1:15–1:55 PM | Panel 4 · Investment, Capital and CommercialisationPanellists to be announced |
1:55–2:35 PM | Panel 5 · Technology, AI and Digital HealthProposed: Sabba Nazhand, Melissa Warner |
2:35–2:50 PM | Afternoon tea |
2:50–3:30 PM | Panel 6 · Education, Careers and Workforce DevelopmentProposed: Merryn Spence Additional panellists to be announced. |
3:30–4:30 PM | Closing Executive RoundtableThe Future of Psychedelic Medicine, Building a Sustainable Global Ecosystem Proposed participant: Pukar Makani Nepal |
4:30–6:00 PM | Symposium Networking Reception |
7:00–9:00 PM | Exclusive PRS27 VIP Dinner |
Clinical models, patient access and real-world treatment.
Clinical trials, next-generation therapies and the pharmaceutical pipeline.
Business models, partnerships and financial structures through the Investment panel and Roundtables.
Clinical evidence, neuroscience and emerging research.
Healthcare delivery, commercialisation and industry partnerships.
Qualifications, competencies, standards and training pathways through the Education, Careers and Workforce Development panel.
Title Sponsor
Confirmed Title Sponsor of PRS27, supporting the Title Sponsor Keynote on Saturday 20 March.

Confirmed Title Sponsor · entropyneurodynamics.com
Connect with healthcare professionals, pharmaceutical executives, researchers, investors, educators and decision-makers.
Panel sponsorship, exhibition and networking partnerships.
Conference publication advertising and digital exposure. A PRS27 conference booklet and online industry directory are being developed.
Direct access to a senior professional audience
Brand positioning within an emerging healthcare sector
Thought leadership opportunities
Brand visibility across the symposium
Clinical and industry networking
Relationship development
Access to emerging commercial and healthcare opportunities
Programme participation remains editorially independent and is not included automatically with sponsorship.
Supporting partners
MINDR
Investor Deck
AMAPP, Australian Multidisciplinary Association for Psychedelic Practitioners
Safar
Pharmaceutical companies, biotechnology businesses, medical technology firms and industry partners are invited to enquire about meaningful professional engagement, industry visibility and access to a relevant audience.
March 2027. News, insights and opportunities from the Asia-Pacific summit for psychedelic medicine, investment and clinical innovation.
Presented by Psychedelics.media


Presented by

A specialist publication covering the business, science, regulation and commercial development of psychedelic medicine through news, analysis, executive interviews and its Business of Psychedelics publication.
PRS27 extends that mission by bringing the industry together in person.
When is PRS27?
Friday 19 and Saturday 20 March 2027.
Where is it held?
Le Méridien Melbourne, 20 Bourke Street, Melbourne, Australia.
Who should attend?
Psychiatrists, psychologists, researchers, pharmaceutical executives, investors, healthcare entrepreneurs, educators and students.
Is the focus scientific or business?
Both.
Is networking included?
General events are included with delegate admission. The VIP Dinner is included with the VIP Delegate ticket.
Can I meet speakers and executives?
Yes, through dedicated networking sessions.
Can I sponsor or exhibit?
Yes, subject to package availability.
Will the programme change?
It is subject to final speaker, moderator and session confirmations.
How much are tickets?
General AU$895, Student AU$495 and VIP AU$1,495. A Networking Ticket for the 19 March Official Welcome Networking Reception is available for AU$95.
Where Business Meets Science
The next chapter of psychedelic medicine will be shaped by people who understand both its scientific potential and the realities of building a sustainable healthcare industry. Join them at PRS27.
www.prs27.com
PRS27
Where Business Meets Science
Programme and speaker participation are subject to confirmation.